|
Public Citizen press release
provided by Angela Bradbery
Arthritis Drug Should Be Removed From Market
Arava Linked to Liver Complications and Deaths, Public Citizen Tells FDA
WASHINGTON, D.C. - A prescription arthritis drug has been
linked to an alarmingly high number of severe liver problems, including deaths,
since it came to the market in 1998 and should be taken off the market
immediately, the consumer group Public Citizen said today in a petition to the
Food and Drug Administration (FDA).
Arava, also known as leflunomide and produced by Aventis, was
first marketed in the United States in September 1998 to treat rheumatoid
arthritis. Over the next three years, it was associated with at least 130 cases
of severe liver toxicity, including 56 hospitalizations and 12 deaths, according
to FDA data. Two of those who died were in their 20s.
"To have this many deaths and severe reactions over such
a short time is truly disturbing." said Dr. Sidney Wolfe, director of
Public Citizen's Health Research Group, which submitted the petition. "When
there are other treatments that are more effective and don't endanger patients
as much as this drug, there is absolutely no reason for the FDA to keep Arava on
the market."
In a comparison between Arava and methotrexate, which is an
equally or more effective drug for treatment of rheumatoid arthritis, Public
Citizen found that over the three-year period it has been on the market, Arava
was linked to six times more cases of fatal liver toxicity and 13 times more
reports of hypertension than methotrexate, although there were 6.8 million (5.5
times) more prescriptions filled for methotrexate than Arava during that time.
Additionally, Arava has been associated with 12 cases of the life-threatening
autoimmune disease Stevens-Johnson Syndrome, and methotrexate with none.
Another danger of the drug is that it remains in body tissues
for an extremely long time. Warnings already on its packaging suggest that
byproducts could remain in the body for months, so that even if patients stopped
the drug after an adverse reaction started, the damage could continue to affect
patients for months.
Public Citizen's petition is supported by Dr. David E. Yocum,
director of the Arizona Arthritis Center at Arizona Health Sciences Center, who
recently ended a tenure as chair of the FDA's Arthritis Drugs Advisory
Committee. Yocum said he agrees that the drug should be withdrawn from the
market.
"I do not believe that the general rheumatologist
understands or has any knowledge about these serious and potentially
life-threatening complications," Yocum said in a letter to Wolfe. "I
also agree that providing a black box warning concerning these issues may not be
effective since no one can predict who will suffer from these
complications."
Yocum has recently reported to the FDA the death of one of
his patients from acute liver failure after using Arava.
After similar serious reactions to leflunomide in Europe, the
European Agency for the Evaluation of Medicinal Products issued an urgent
warning last year to patients and doctors about the drug's toxicity.
"Before it was approved by the FDA, there was evidence
that leflunomide led to liver complications, and now the dangers are even
clearer," Wolfe said. "No more patients should be subjected to these
risks."
A copy of the petition can be viewed on the Web at http://www.citizen.org/documents/1614.pdf.
Public Citizen is a nonprofit consumer advocacy organization based in
Washington, D.C. Fore more information, visit www.citizen.org.
END QUOTE
just substitute the word "Carprofen" for the word "leflunomide"
- of course with "carprofen" the death rate is MUCH higher!
http://www.fda.gov/cvm/index/ade/adetoc.htm
Year 1997 Carprofen - Oral Dog
1244
Reports 1370 Treated 1327
Reacted 195
Died
Year 1998 Carprofen - Oral Dog
3352 Reports 3431 Treated 3401
Reacted 456
Died
Year 1999 Carprofen - Oral Dog
2440 Reports 2513 Treated 2452
Reacted 371 Died
Year 2000 Carprofen - Oral Dog
2419 Reviews 2566 Treated
2460 Reacted 470
Died
statistical data provided by
Jean
(Always for George - Always for the Rimadyl Dogs)
For Pros and Cons see: www.srdogs.com/Pages/rimadylfr.html
ABRADBERY@citizen.org Angela
Bradbery
Back |